Blog | HemaCare

HemaCare PBMCs Provide Vital Data for CAR T Cell Primate Study

Aug 25, 2020 10:04:00 AM / by Nancy Andon, MSc posted in CAR-T, PBMCs

0 Comments

A recent collaborative study published by Amgen and Kite Pharma cites the use of HemaCare sourced peripheral blood mononuclear cells (PBMC) in their investigative effort on the development of a novel CAR T cell therapy. [1]

Acute myeloid leukemia (AML) is a form of blood cancer characterized by the rapid buildup of abnormal cells in the bone marrow. The disease affects about a million people globally and, tragically, has a less than 30% survival rate.

Read More

HemaCare PBMCs Aid Development of Novel Cancer Immunotherapy

Aug 4, 2020 10:01:00 AM / by Nancy Andon, MSc posted in Cancer, PBMCs, Immunotherapy (Immunology)

0 Comments

A paper published in the journal Blood cites the use of HemaCare-sourced peripheral blood mononuclear cells (PBMCs) to test a murine model of a new antibody-based cancer immunotherapy.

Multiple myeloma (MM) is a life-threatening disease that accounts for 10-15% of all blood-based cancers. The disease occurs when a specific group of white blood cells, known as plasma cells, become malignant. T cell therapy has shown some promise in treating the disease on a temporary basis, but with very few cancer-specific targets identified, MM remains incurable.

Read More

Mimicking Memory Cell Activation

Jun 23, 2020 10:08:00 AM / by Nancy Andon, MSc posted in B Cells, PBMCs, T Cells

0 Comments

An independent study carried out at a Cellular Technology Ltd. cites using HemaCare PBMCs in their efforts to replicate physiological B cell activation in an assay format. [1]

Memory B cells function as the foundation of the adaptive immune system, creating a physiological catalogue of foreign antigens that can be used to “recognize” invading pathogens and trigger an immune response. Memory B cells can survive for decades, creating long-term protection against diseases that have been encountered previously.

Read More

HemaCare PBMCs Aid HPV Cancer Research

Apr 7, 2020 10:07:00 AM / by Nancy Andon, MSc posted in Cancer, PBMCs, T Cells

0 Comments

Cell therapy starting materials sourced from HemaCare are being used to support studies focused on the selective expansion of tumor-specific T cells.

In a recent article, [1] researchers at a Cambridge, MA biotech company describe their work with a fusion protein designed to specifically activate and expand killer T cells that recognize human papilloma virus associated (HPV+) head and neck cancer cells.

Read More

HemaCare PBMCs Power Exosome-based Cancer Immunotherapy

Mar 3, 2020 10:02:00 AM / by Nancy Andon, MSc posted in Cancer, PBMCs, Immunotherapy (Immunology)

0 Comments

In a recent study, scientists at UCLA medical school cited using HemaCare sourced PBMCs for their research into a novel cancer immunotherapy strategy. [1]

This promising new strategy is based on cellular structures known as exosomes, which are small membrane-bound packets used to deliver protein “messages” from cell to cell. Because exosomes are known to facilitate cell-to-cell communications, researchers were keen to figure out whether they could be used to communicate the information immune cells need to target cancer.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts